| Patent Number |
Title Of Patent |
Date Issued |
| 6136544 |
Glutamate receptor (or EAA receptor) polynucleotides and their uses |
October 24, 2000 |
| Human CNS receptor-encoding DNA is provided from which more than one form of the receptor protein, an edited form and an unedited form, is expressed in vivo. The edited and unedited receptor forms are functionally distinct, and appear to be selectively expressed. Thus, a CNS receptor-enc |
| 6133287 |
Piperidine-indole compounds having 5-HT.sub.6 affinity |
October 17, 2000 |
| Described herein are compounds with affinity for the 5-HT.sub.6 receptor, which have the general formula: wherein:R.sup.1 is selected from the group consisting of H and C.sub.1-4 alkyl;R.sup.2 is selected from the group consisting of H, C.sub.1-4 alkyl and benzyl;-- -- -- represents a single |
| 6103715 |
Dopamine receptor ligands |
August 15, 2000 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH-- |
| 6100291 |
Pyrrolidine-indole compounds having 5-HT.sub.6 affinity |
August 8, 2000 |
| Described herein are compounds with affinity for the 5-HT.sub.6 receptor, which have the general formula: ##STR1## wherein: R.sup.1 is selected from the group consisting of H and C.sub.1-4 alkyl;R.sup.2 is selected from the group consisting of H, C.sub.1-4 alkyl and benzyl;R.sup. |
| 6077949 |
Cloned glucagon-like peptide 2 receptors |
June 20, 2000 |
| The invention relates to nucleotides and amino acid sequences encoding glucagon-like peptide 2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications. |
| 6057126 |
Mammalian EDG-5 receptor homologs |
May 2, 2000 |
| The present invention describes a nucleic acid sequence and an amino acid sequence for novel mammalian, including human, EDG-5 receptor homologs. |
| 6040175 |
AMPA-binding human GluR2 receptors |
March 21, 2000 |
| Described herein are isolated polynucleotides which code for an AMPA-type human CNS glutamate receptor, designated the human GluR2B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing these receptor is disclosed. |
| 6020158 |
Isolated polynucleotide for novel G-protein coupled receptor |
February 1, 2000 |
| The present invention is directed to an isolated polynucleotide for novel G-Protein Coupled Receptors. More particularly, the present invention provides an isolated polynucleotide comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 o |
| 6018023 |
Kainate-binding, human CNS receptors of the EAA3 family |
January 25, 2000 |
| Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of the kainate-binding type of EAA receptor, has now been isolated and the receptor protein characterized. Herein described are recombinant cel |
| 6013768 |
Kainate-binding human CNS receptors of the EAA1 family |
January 11, 2000 |
| Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein describe |
| 5998462 |
5-alkyl indole compounds |
December 7, 1999 |
| Described herein are compounds selective for the 5-HT.sub.1D -like receptor, which have the general formula: ##STR1## wherein: R.sup.1 is linear or branched loweralkyl;R.sup.2 is selected from a group of Formula II, III, IV and V: ##STR2## R.sup.3 is selected from H and loweralky |
| 5998438 |
5-cyclo indole compounds |
December 7, 1999 |
| Described herein are compounds selective for a 5-HT.sub.1D -like receptor, which have the general formula: ##STR1## wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle havi |
| 5968478 |
N- methyl piperazine compounds having dopamine receptor affinity |
October 19, 1999 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein X.sub.1 is selected from CH.sub.2, NH, O and S;X.sub.2 -- is selected from CH=, CH.sub.2 --, and N=;R.sub.1 to R.sub.8 are each independently selected from H, C.sub.1-4 alkyl, halo, cyano, n |
| 5856510 |
5-alkenyl and 5-alkynyl indole compounds |
January 5, 1999 |
| Described herein are compounds selective for 5-HT.sub.1D -like receptors, which have the general formula: ##STR1## wherein: R.sup.1 is selected from H, aryl and aryl substituted with 1, 2 or 3 substituents independently selected from loweralkyl, loweralkoxy, loweralkylcarbonyl, l |
| 5849734 |
Muscarinic receptor ligands |
December 15, 1998 |
| Described herein are D4 receptor-selective compounds of the general formula I: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH |
| 5834459 |
Alkyl-substituted compounds having dopamine receptor affinity |
November 10, 1998 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH--N |
| 5831001 |
Treatment of herpesvirus infection |
November 3, 1998 |
| Described herein are oligopeptides useful to inhibit replication of herpesviruses, especially herpes simplex viruses. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 5 uM concentration, exhib |
| 5830712 |
Selective template deletion method |
November 3, 1998 |
| A novel method for inactivating undesirable members in a nucleic acid sample which comprises undesirable and desirable members of a nucleic acid family. The method includes the step of adding a blocker to the sample which selectively associates with the undesirable members such that they |
| 5824676 |
5-HT2 receptor ligands |
October 20, 1998 |
| Described herein are 5-HT2 receptor-selective compounds of Formula I: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH- |
| 5814628 |
Benzyl-substituted compounds having dopamine receptor affinity |
September 29, 1998 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH-- |
| 5798350 |
Dopamine receptor ligands |
August 25, 1998 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH-- |
| 5770742 |
Thiophene-tryptamine derivatives |
June 23, 1998 |
| 5-Thiophene-substituted tryptamine analogs are provided, which exhibit selectivity towards 5-HT.sub.D1 receptors and consequently show potential in alleviation of the symptoms of migraine. The analogs are represented by the following general chemical formula: ##STR1## in which X |
| 5700445 |
N-methyl piperazine compounds having dopamine receptor affinity |
December 23, 1997 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein X.sub.1 is selected from CH.sub.2, NH, O and S;X.sub.2 - - is selected from CH.dbd., CH.sub.2 13 , and N.dbd.;R.sub.1 to R.sub.8 are each independently selected from H, C.sub.1-4 alkyl, hal |
| 5674877 |
Muscarinic receptor ligands |
October 7, 1997 |
| Described herein are D4 receptor-selective compounds of the general formula I: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH |
| 5674849 |
Anti-viral compositions |
October 7, 1997 |
| An anti-viral composition includes a synergistic combination of an anti-viral nucleoside analogue, which may inhibit a virus-specific enzyme, such as viral thymidine kinase and reverse transcriptase, an anti-viral oligonucleotide compound having from 6 to 12 amino acid residues subst |
| 5646120 |
Peptide-based inhibitors of HIV replication |
July 8, 1997 |
| Described herein are oligopeptides useful to inhibit replication in virally infected individuals. In a preferred embodiment of the invention, the oligopeptide is a D-arginine nonamer having N- and C-terminal protecting groups, which, at a 5 uM concentration, exhibits greater than 95% |
| 5643785 |
Polynucleotides encoding AMPA-binding human GluR4 receptors |
July 1, 1997 |
| Described herein are isolated polynucleotides which code for an AMPA-type human CNS receptor, designated the human GluR4B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing the receptor is disclosed. |
| 5633230 |
Treatment of cytomegalovirus infection |
May 27, 1997 |
| Described herein are anti-cytomegalovirus peptides. In a preferred embodiment, the peptide is acetyl-[D-Arg].sub.9 -NH.sub.2. The use of these peptides, either per se or in combination with other anti-CMV compounds, is disclosed as an effective method for controlling CMV infection. |
| 5629205 |
Promoters for gene expression |
May 13, 1997 |
| The present invention provides a novel expression system for the production of protein in bacterial hosts. The system utilizes novel promoters that are highly efficient in initializing transcription and therefore enhance protein yield. The promoters comprise the -35 region of the consens |
| 5627194 |
Anti-viral guanidino-substituted compounds |
May 6, 1997 |
| Novel guanidino-substituted compounds are described having the following general formula (I): ##STR1## in which X may be carbon, oxygen, nitrogen or sulfur; R.sub.1 may be H, OH, linear or branched lower alkyl, lower alkoxy, lower (alkyl-substituted alkoxy), lower alkyl-amine, lo |
| 5616481 |
Kainate-binding human CNS receptors of the EAA1 family |
April 1, 1997 |
| Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein describe |
| 5614406 |
Kainate-binding human CNS receptors of the EAA2 family |
March 25, 1997 |
| Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein describe |
| 5602124 |
5-HT2 receptor ligands |
February 11, 1997 |
| Described herein are 5-HT2 receptor-selective compounds of Formula I: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH--OH, CH- |
| 5602121 |
Alkyl-substituted compounds having dopamine receptor affinity |
February 11, 1997 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH-- |
| 5602120 |
Benzyl-substituted compounds having dopamine receptor affinity |
February 11, 1997 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH-- |
| 5599792 |
Bone-stimulating, non-vasoactive parathyroid hormone variants |
February 4, 1997 |
| Described herein are Met.sup.8 -substituted variants of parathyroid hormone that retain bone stimulating activity yet, unlike their native counterparts, have substantially no vasoactivity. Their production using recombinant DNA-based techniques is also described, as is their therapeu |
| 5576314 |
Bicyclic nonane and decane compounds having dopamine receptor affinity |
November 19, 1996 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH-- |
| 5576205 |
Kainate-binding human CNS receptors of the EAA1 family |
November 19, 1996 |
| Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein describe |
| 5574144 |
Kainate-binding, human CNS receptors of the EAA4 family |
November 12, 1996 |
| Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors of the kainate-binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described |
| 5561127 |
Muscarinic receptor ligands |
October 1, 1996 |
| Described herein are D4 receptor-selective compounds of the general formula I: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH |
| 5547855 |
Kainate-binding human CNS glutamate receptors EAA3C and EAA3D, DNA encoding them, and expression |
August 20, 1996 |
| Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of the kainate-binding type of EAA receptor, has now been isolated and the receptor protein characterized. Herein described are recombinant cel |
| 5538965 |
Dopamine receptor ligands |
July 23, 1996 |
| Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;X.sub.1 is selected from CH.sub.2, O, NH, S, C.dbd.O, CH-- |
| 5504101 |
5-HT-1D receptor ligands |
April 2, 1996 |
| Described herein are tryptamine analogs that display high binding affinity and selectivity for the 5-HT1D.beta. receptor, of the formula: ##STR1## wherein R.sup.1 is a group selected from aryl-C.sub.1-7 alkyl; aryl-C.sub.2-7 alkoxy; aryl-C.sub.2-7 alkanoyl and aryl-C.sub.1-7 alka |
| 5496801 |
Parathyroid hormone formulation |
March 5, 1996 |
| Described herein are preparations containing parathyroid hormone that has been stablized with an excipient and buffering agent. Preferred preparations incorporate human PTH(1-84), mannitol as excipient and citrate as buffering agent, and are incorporated in vials as a freeze-dried po |
| 5495006 |
Antiviral polynucleotide conjugates |
February 27, 1996 |
| The herpes simplex virus encodes ICP4, a DNA binding protein. ICP4-binding duplexed structures having significantly enhanced stability under physiological conditions are described. The structures are provided in the form of polynucleotide conjugates capable of adopting a duplexed str |
| 5494792 |
Kainate-binding, human CNS receptors of the EAA2 family |
February 27, 1996 |
| Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors, of the kainate binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein describe |
| 5432080 |
DNA encoding variants of human corticosteroid binding globulin |
July 11, 1995 |
| A novel steroid-binding variant of human corticosteroid binding globulin in which one or more of the glycosylation sites, other than the glycosylation site at amino acid position 238, has been functionally disrupted is complexed with an anti-inflammatory ligand in the treatment of in |
| 5403825 |
Method for isolating a soluble osteogenic factor from bone |
April 4, 1995 |
| Described is a purified osteogenic factor that when delivered to bone in association with a physiologically acceptable delivery vehicle is capable of inducing new bone growth at the bone surface. The osteogenic factor is water soluble, and is characterized physically by a molecular weigh |
| 5382658 |
Stability-enhanced variants of parathyroid hormone |
January 17, 1995 |
| Herein described are variants of parathyroid hormone that retain significant PTH activity and are substantially resistant to trypsin and trypsin-like enzymes. The variants are useful pharmaceutically, to treat bone disorders such as osteoporosis and in other therapeutic applications. |
| 5344819 |
Pharmaceutical compositions for use in treating inflammation |
September 6, 1994 |
| Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG) that is produced by recombinant DNA-based techniques. |
